FIELD: medicine.
SUBSTANCE: invention refers to medical devices, particularly to implantable devices for treating a vascular disease in the patients with type 2 diabetes. The device comprises an intraluminal frame structure, and first and second agents in combination, together coupled with the intraluminal frame structure. The first and second agents are included into polymer matrixes for the controlled release over various periods of time, and directly into the tissue surrounding the intraluminal device. The first agent representing a mTOR inhibitor is used to inhibit local restenosis. The device is designed so that a large part of the mTOR inhibitor is released over the first period of time of 60 days or less. The second agent representing an insulin sensitiser aims at enhancing set of vascular cell functions nearby the intraluminal device. The device is configured so that a therapeutically effective portion of the insulin sensitiser is released within a second period of time, which lasts for more than one hundred and eighty days.
EFFECT: device enables treating acute and chronic manifestations of the vascular disease in the patients with type 2 diabetes.
7 cl, 13 tbl, 95 dwg
